Latest Market Share News

Perseus Mining has reported record FY25 financial results with a 16% rise in profit after tax and announced a 50% increase in dividends alongside a renewed A$100 million share buyback program.

Sprintex Limited reported a 26% revenue increase for FY25 but also a 37% rise in net loss, as it accelerates global expansion through key distribution deals and manufacturing upgrades.

MotorCycle Holdings Limited delivered a robust FY2025 performance, marked by double-digit revenue growth, significant debt reduction, and expanding market share in new and used motorcycles.

Wesfarmers Limited reported a 14.4% rise in net profit for FY2025, driven by strong retail performances and strategic portfolio moves. The company also announced a fully-franked final dividend and a significant capital management distribution, signaling confidence amid economic headwinds.

MotorCycle Holdings Limited has delivered a standout FY2025 performance, posting record revenue and profit while slashing debt and expanding its market footprint. The company’s strategic moves into off-highway vehicles and digital channels signal a bold growth trajectory for FY2026.

NextEd Group reported a 13.9% revenue decline in FY25, yet maintained resilient EBITDA and strengthened its cash position, signaling a strategic reset underway to capture future growth.

Thorney Opportunities Ltd posted a sharp 76% decline in profit after tax for FY2025 yet declared a higher fully franked final dividend and reported growth in net tangible assets per share.

Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.

Nova Eye Medical has reported a record A$29.3 million in FY25 revenue, driven by sustained US growth and operational improvements, setting the stage for breakeven EBITDA in the first half of FY26.

Compumedics has reported record-breaking sales orders and revenues for FY25, driven by strong US market growth and SaaS adoption, setting the stage for an ambitious FY26 expansion.

L1 Long Short Fund Limited reported a net profit after tax of $99.52 million for FY2025, down 42% year-on-year, yet continues its steady dividend growth with a fully franked final dividend of 6.5 cents per share.

Neuren Pharmaceuticals reported a robust half-year with an 88% increase in net profit, driven by rising royalties from DAYBUE™ sales and progress in its NNZ-2591 clinical program. The company also completed a $39.6 million share buy-back, underscoring confidence in its growth trajectory.